Hans J Hartling1, Lise W Thørner, Christian Erikstrup, Lene H Harritshøj, Gitte Kronborg, Court Pedersen, Carsten S Larsen, Marie Helleberg, Jan Gerstoft, Niels Obel, Henrik Ullum, Susanne D Nielsen. 1. aDepartment of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark bViro-Immunology Research Unit cDepartment of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen dDepartment of Clinical Immunology, Aarhus University Hospital, Aarhus eDepartment of Infectious Diseases, Hvidovre, Copenhagen University Hospital, Copenhagen fDepartment of Infectious Diseases, Odense University Hospital, Odense gDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
Abstract
OBJECTIVES: To investigate single-nucleotide polymorphisms (SNPs) in the gene encoding interleukin-7 receptor α (IL7RA) as predictors for CD4⁺ T-cell change after initiation of combination antiretroviral therapy (cART) in HIV-infected whites. DESIGN: SNPs in IL7RA were determined in the Danish HIV Cohort Study. METHODS: CD4⁺ T-cell changes were estimated 6 months, 1, 2, and 5 years after initiation of cART in 1683 HIV-infected virally suppressed individuals. Five SNPs in IL7RA were examined as predictors for CD4⁺ T-cell change in the first (0-6 months after initiation of cART) and second phase (>6 months after initiation of cART) of immune recovery. Univariable and multivariable analyses including age, sex, calendar period, CD4⁺ nadir, and baseline CD4⁺ T-cell count and viral load as covariates were performed. RESULTS: Individuals carrying two T-alleles in rs6897932 had faster CD4⁺ T-cell recovery compared with individuals carrying a C-allele in the first phase of immune recovery [mean CD4⁺ T-cell change, cells/μL (95% confidence interval), in TT: 177 (151-203), CT: 131 (119-143), CC: 141 (132-151), P = 0.018]. No isolated effect of rs6897932 on CD4⁺ T-cell change was found in the second phase of immune recovery; however, the initial difference in CD4⁺ T-cell recovery remained during 5 years. The effect was most pronounced in individuals above 40 years of age. CONCLUSION: T-allele homozygosity in rs6897932 is a predictor for faster CD4⁺ T-cell recovery after initiation of cART in HIV-infected whites, however, only in the first phase of immune recovery.
OBJECTIVES: To investigate single-nucleotide polymorphisms (SNPs) in the gene encoding interleukin-7 receptor α (IL7RA) as predictors for CD4⁺ T-cell change after initiation of combination antiretroviral therapy (cART) in HIV-infected whites. DESIGN: SNPs in IL7RA were determined in the Danish HIV Cohort Study. METHODS:CD4⁺ T-cell changes were estimated 6 months, 1, 2, and 5 years after initiation of cART in 1683 HIV-infected virally suppressed individuals. Five SNPs in IL7RA were examined as predictors for CD4⁺ T-cell change in the first (0-6 months after initiation of cART) and second phase (>6 months after initiation of cART) of immune recovery. Univariable and multivariable analyses including age, sex, calendar period, CD4⁺ nadir, and baseline CD4⁺ T-cell count and viral load as covariates were performed. RESULTS: Individuals carrying two T-alleles in rs6897932 had faster CD4⁺ T-cell recovery compared with individuals carrying a C-allele in the first phase of immune recovery [mean CD4⁺ T-cell change, cells/μL (95% confidence interval), in TT: 177 (151-203), CT: 131 (119-143), CC: 141 (132-151), P = 0.018]. No isolated effect of rs6897932 on CD4⁺ T-cell change was found in the second phase of immune recovery; however, the initial difference in CD4⁺ T-cell recovery remained during 5 years. The effect was most pronounced in individuals above 40 years of age. CONCLUSION: T-allele homozygosity in rs6897932 is a predictor for faster CD4⁺ T-cell recovery after initiation of cART in HIV-infected whites, however, only in the first phase of immune recovery.
Authors: M Guzmán-Fulgencio; J Berenguer; D Pineda-Tenor; M A Jiménez-Sousa; M García-Álvarez; T Aldámiz-Echevarria; A Carrero; C Diez; F Tejerina; S Vázquez; V Briz; S Resino Journal: Eur J Clin Microbiol Infect Dis Date: 2014-09-19 Impact factor: 3.267
Authors: Ngomu Akeem Akilimali; Daniel M Muema; Charles Specht; Christina C Chang; Mahomed-Yunus S Moosa; Stuart M Levitz; Sharon R Lewin; Martyn A French; Thumbi Ndungʼu Journal: J Acquir Immune Defic Syndr Date: 2019-04-15 Impact factor: 3.731
Authors: Jeffrey A Boatman; Jason V Baker; Sean Emery; Hansjakob Furrer; David M Mushatt; Dalibor Sedláček; Jens D Lundgren; James D Neaton Journal: J Acquir Immune Defic Syndr Date: 2019-05-01 Impact factor: 3.731
Authors: María Guzmán-Fulgencio; Juan Berenguer; María A Jiménez-Sousa; Daniel Pineda-Tenor; Teresa Aldámiz-Echevarria; Pilar García-Broncano; Ana Carrero; Mónica García-Álvarez; Francisco Tejerina; Cristina Diez; Sonia Vazquez-Morón; Salvador Resino Journal: J Transl Med Date: 2015-06-30 Impact factor: 5.531
Authors: Marco Gelpi; Hans J Hartling; Kristina Thorsteinsson; Jan Gerstoft; Henrik Ullum; Susanne D Nielsen Journal: BMC Infect Dis Date: 2016-10-21 Impact factor: 3.090